Clinical Trial

Precision Retrospective Integrative Study for Metastatic Lymph Nodes in Breast Cancer

Study acronym: PRISM
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2024 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Accurate assessment of axillary lymph nodes in patients with breast cancer is essential for prognosis and treatment planning. Staging and surgical management have evolved from axillary lymph node dissection to sentinel lymph node biopsy to minimize morbidity. However, sentinel lymph node biopsy has non-negligible morbidity, and more than 70% of biopsies are negative, calling into question its routine use. Magnetic resonance imaging (MRI) can be used to detect and stage lymph node metastases in situ, but its sensitivity and specificity are moderate to poor. Few studies have employed artificial intelligence to detect lymph node metastases on MRI images, and none have used an integrative multidata approach (IMA), defined as modeling the combination of clinical and laboratory data with multiparametric MRI. The primary objective of this retrospective observational study is to improve the accuracy of detecting lymph node involvement in breast cancer using IMA. The secondary objective is to allow longitudinal monitoring of the effects of neoadjuvant therapy on lymph node involvement
Trial Details
NCT Number NCT06738459
Lead Sponsor Centro di Riferimento Oncologico - Aviano
Conditions Breast Cancer
Enrollment 1,500 participants
Start Date 2025-01-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-17